Macrocyclic Compounds Targeting KRAS and HIF-1α Pathways
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies targeting microtubules often have limited selectivity and efficacy, particularly in addressing oncogenic KRAS and HIF-1α pathways, necessitating the development of novel microtubule-targeting agents with improved specificity and antiproliferative effects.
Innovation Solution
The identification and development of macrocyclic compounds, such as Gatorbulin-1 (GB1) and Gatorbulin-2 (GB2), which act as microtubule-destabilizing cyclodepsipeptides, preferentially targeting cancer cells over normal cells and inhibiting HIF-1α and KRAS pathways, thereby modulating proliferation activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional microtubule-targeting agents are used, then antiproliferative effects are achieved, but selectivity against cancer cells with specific oncogenic pathways (KRAS, HIF-1α) is insufficient
Solution Approach 1:
The patent applies local quality by designing macrocyclic compounds with specific structural features (hydroxyl group configurations, ring sizes, stereochemistry) that enable selective binding to microtubules in cancer cells with specific oncogenic pathways. The compounds have differentiated local chemical properties (e.g., specific R group configurations in Formula I) that confer preferential activity against KRAS- and HIF-1α-containing cells while sparing normal cells.
2Productivity
If current cancer therapies are used, then general antiproliferative activity is achieved, but efficacy against specific oncogenic pathways (KRAS, HIF-1α) is limited
Solution Approach 1:
The patent employs parameter changes by systematically varying molecular parameters of the macrocyclic compounds including ring size, substituent types (R groups), stereochemistry, and functional group positions. These parameter modifications result in compounds with enhanced and differentiated antiproliferative activity profiles, showing preferential potency against cancer cell lines with specific oncogenic pathways while maintaining general microtubule-targeting mechanisms.
Data Source
AI summary
The instant invention describes macrocyclic compounds having antiproliferation activity, and methods of treating disorders such as cancer, tumors and cell proliferation related disorders.